title: Multi-step regulation of interferon induction by hepatitis C virus.
abstract: Acute hepatitis C virus (HCV) infection evokes several distinct innate immune responses in host, but the virus usually propagates by circumventing these responses. Although a replication intermediate double-stranded RNA is produced in infected cells, type I interferon (IFN) induction and immediate cell death are largely blocked in infected cells. In vitro studies suggested that type I and III IFNs are mainly produced in HCV-infected hepatocytes if the MAVS pathway is functional, and dysfunction of this pathway may lead to cellular permissiveness to HCV replication and production. Cellular immunity, including natural killer cell activation and antigen-specific CD8 T-cell proliferation, occurs following innate immune activation in response to HCV, but is often ineffective for eradication of HCV. Constitutive dsRNA stimulation differs in output from type I IFN therapy, which has been an authentic therapy for patients with HCV. Host innate immune responses to HCV RNA/proteins may be associated with progressive hepatic fibrosis and carcinogenesis once persistent HCV infection is established in opposition to the IFN system. Hence, innate RNA sensing exerts pivotal functions against HCV genome replication and host pathogenesis through modulation of the IFN system. Molecules participating in the RIG-I and Toll-like receptor 3 pathways are the main targets for HCV, disabling the anti-viral functions of these IFN-inducing molecules. We discuss the mechanisms that abolish type I and type III IFN production in HCV-infected cells, which may contribute to understanding the mechanism of virus persistence and resistance to the IFN therapy.
authors.affiliation: Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Kita, Sapporo 060-8638, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Oshiumi
authors.forename: Kenji
authors.initials: K
authors.lastname: Funami
authors.forename: Hussein H
authors.initials: HH
authors.lastname: Aly
authors.forename: Misako
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Seya
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000276:immunology; D000818:Animals; D005786:Gene Expression Regulation / Q000276:immunology; D016174:Hepacivirus / Q000276:immunology*; D006526:Hepatitis C / Q000276:immunology* / Q000628:therapy; D022781:Hepatocytes / Q000276:immunology* / Q000821:virology; D006801:Humans; D057131:Immune Evasion; D007113:Immunity, Innate; D007167:Immunotherapy; D007372:Interferons / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D012367:RNA, Viral / Q000276:immunology; D015398:Signal Transduction; D016896:Treatment Outcome
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C505371:MAVS protein, human; D012367:RNA, Viral; D007372:Interferons